Form 4: OptimizeRx CEO William Febbo Receives 15,000 Restricted Stock Units

OptimizeRx CEO William Febbo was granted 15,000 restricted stock units that will vest on February 15, 2025.

Summary

• William J Febbo, CEO of OptimizeRx Corp, received 15,000 restricted stock units on February 15, 2024.
• These restricted stock units represent a contingent right to receive shares of OptimizeRx common stock.
• The units will vest in full on February 15, 2025, the first anniversary of the grant date.
• Following the transaction, Febbo beneficially owns 553,144 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of restricted stock units is a standard practice and signals confidence in the company's future performance.

Positives

• The grant of restricted stock units aligns the CEO's interests with those of the shareholders, incentivizing him to drive long-term value creation.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting date of the restricted stock units.

Industry Context

Grants of restricted stock units are a common form of executive compensation in the technology and healthcare industries, aligning management incentives with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including restricted stock units, are common in publicly traded companies like OptimizeRx. Companies such as Veeva Systems and Teladoc Health also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedule of one year is fairly standard. Some companies use multi-year vesting schedules to further incentivize long-term performance.

Stakeholder Impact

• The grant of restricted stock units to the CEO can positively impact shareholders by aligning management's interests with long-term value creation.

Key Dates